MEDVi QUAD vs Rugiet Ready: We Spent 30 Hours Researching Both — Here's What Actually Matters

QUAD and Rugiet are the two serious contenders in the multi-ingredient sublingual ED space. Both combine PDE5 inhibitors with apomorphine. Both skip the pill format. But the differences — in what's inside, how they're delivered, and what they cost — are bigger than most comparison articles let on. We dug into the clinical literature, user reviews, and pricing structures to figure out which one makes more sense, and for whom.

The ingredient gap is the whole story

If you strip away the marketing, there's really one fundamental difference between these two products: vardenafil.

Rugiet Ready combines sildenafil, tadalafil, and apomorphine. It was the first product to do this when it launched in 2019, and it deserves credit for creating the category. Three ingredients, two PDE5 inhibitors plus a dopamine agonist. It works well for a lot of men.

QUAD takes that same foundation and adds vardenafil — the active ingredient in Levitra, and the third major PDE5 inhibitor. This isn't a token addition. Vardenafil has a distinct pharmacological profile: it's consistently the fastest-acting of the three PDE5 inhibitors in clinical trials, and it demonstrates strong potency at relatively low doses. For men who respond well to vardenafil specifically, this is a meaningful inclusion. For men who've only tried sildenafil or tadalafil and haven't gotten ideal results, having a third PDE5 mechanism in play broadens the likelihood of response.

To put it plainly: Rugiet covers two of the three PDE5 pathways. QUAD covers all three. Both include apomorphine for the desire component. The question is whether that third pathway matters enough to justify the switch.

The format difference matters more than you'd think

Rugiet Ready is a sublingual troche — a solid lozenge that you place under your tongue and let dissolve over 5–10 minutes. In theory, this works well. In practice, there's a problem.

Rugiet's troches soften above 70°F. That's not a rare temperature — it's a warm room. A car in summer. A pocket during a dinner out. Rugiet ships their product with ice packs and recommends refrigerator storage. If you read through their TrustPilot reviews, the melting issue comes up constantly. The medication still works after melting and re-solidifying, but the form factor is compromised, dosing becomes imprecise, and the experience is just frustrating.

QUAD sidesteps this entirely by using a liquid format. There's nothing to melt because it's already liquid. You measure the dose with a dropper, place it under your tongue, hold for 60–90 seconds, done. No temperature sensitivity, no refrigeration required, no guesswork if it got too warm.

The liquid format also has a pharmacokinetic advantage. With a troche, the drug needs to dissolve first before it can be absorbed through the sublingual membrane. With a liquid, the active ingredients are already in solution — absorption begins immediately on contact. This likely accounts for QUAD's slightly faster onset (10–15 minutes vs Rugiet's 15 minutes).

Pricing: it's closer than it looks

Rugiet Ready's pricing structure can be confusing because it varies by strength. Here's how it actually breaks down:

If you're comparing against Rugiet's low tier, Rugiet is cheaper. Against the medium or high tier, QUAD is comparable or less — and you're getting an additional ingredient. On a cost-per-clinically-proven-ingredient basis, QUAD comes out ahead at roughly $30 per ingredient per month vs. $27–$47 for Rugiet.

Neither product is cheap compared to popping a generic sildenafil pill for $3. But neither product is trying to be that. These are premium combination treatments for men who've moved past the single-ingredient phase.

Where Rugiet still wins

This wouldn't be an honest comparison if we didn't acknowledge what Rugiet does better.

Track record and reviews

Rugiet has been on the market since 2019. They have 1,167+ verified reviews on TrustPilot averaging 4.0 out of 5 stars. That's a real body of evidence from real users. QUAD is newer with a smaller user base — roughly 5,000 users. The product science is strong, but the user validation is still catching up. For men who want to see thousands of people confirm "yes, this works" before committing, Rugiet has a substantial lead.

Dosing customization

Rugiet's physicians can adjust the ratio of each ingredient — increasing sildenafil while reducing tadalafil, for example, or fine-tuning the apomorphine dose. They offer four documented strength tiers and the flexibility to go beyond them based on patient feedback. QUAD offers clinician-guided dosing, but the level of documented customization granularity isn't as detailed in their public materials.

Brand recognition

If you mention Rugiet in a men's health forum, people know what it is. QUAD is still building that name recognition. This doesn't affect how the medication works, but it does affect how comfortable some men feel trying it.

Side effects: essentially the same baseline

Both products share the same core ingredients (sildenafil, tadalafil, apomorphine) so the side effect profile overlaps heavily. Expect the same set of common effects: headache, nasal congestion, facial flushing, occasional dizziness. Apomorphine can cause mild nausea in both products.

The meaningful difference is that QUAD includes a third PDE5 inhibitor. In theory, this could slightly increase the probability or intensity of PDE5-related side effects. In practice, compounded dosing allows clinicians to use lower individual doses of each ingredient — the intent is broader coverage at gentler per-ingredient levels, not a higher total drug load.

Both products are contraindicated with nitrate medications. Both require a clinician review before prescribing. The safety profile is well-established for all ingredients in both formulas.

Who should choose which

Our bottom line

Both products work. Both are legitimate compounded ED medications prescribed through telehealth platforms. The decision comes down to what you prioritize.

Rugiet Ready is the proven choice. It's been around for seven years, it has a mountain of user reviews, and the customization options are genuinely useful for men who need precise dose titration. Its weaknesses — the melting problem, only two PDE5 inhibitors, higher per-ingredient cost at upper tiers — are real but not dealbreakers.

QUAD is the more scientifically complete product. Four proven ingredients, liquid delivery, no temperature sensitivity, competitive pricing. Its weakness is newness — fewer user reviews, less brand recognition. But the ingredient profile is objectively stronger, and the liquid format solves a real practical problem that affects Rugiet daily.

For men who've tried Rugiet and are happy with it, stay. For men making a fresh decision, or for anyone who's been frustrated by Rugiet's limitations, QUAD is worth a serious look.

Frequently Asked Questions

More Comparisons & Reviews